ArticleDisease markers2022
Prognosis Risk Model Based on Pyroptosis-Related lncRNAs for Bladder Cancer.
Article in Disease markers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 16 citations in OpenAlex.
- Prognostic risk model of six m7 g-related lncRNAs in lung adenocarcinoma.European journal of medical research · 2025Article
- Role of N6-methyladenosine RNA modification in cancer.MedComm · 2024Review
- The Role of Pyroptosis in the Progression and Targeted Therapeutic Approaches for Urological Malignancies.Journal of inflammation research · 2024Review
- Identification of necroptosis-related long non-coding RNAs prognostic signature and the crucial lncRNA in bladder cancer.Journal of cancer research and clinical oncology · 2023Article
- Identification of m6A-related lncRNAs as prognostic signature within colon tumor immune microenvironment.Cancer reports (Hoboken, N.J.) · 2023Article
- Prognosis Risk Model Based on Pyroptosis-Related lncRNAs for Gastric Cancer.Biomolecules · 2023Article
- Construction and validation of a bladder cancer risk model based on autophagy-related genes.Functional & integrative genomics · 2023Article
- Identification of platinum resistance-related gene signature for prognosis and immune analysis in bladder cancer.Frontiers in genetics · 2023Article
- m7G-related lncRNAs are potential biomarkers for predicting prognosis and immune responses in patients with oral squamous cell carcinoma.Frontiers in genetics · 2022Article
- A novel prognostic signature based on cuproptosis-related lncRNA mining in colorectal cancer.Frontiers in genetics · 2022Article
- Novel Pyroptosis-Related Gene Signatures Identified as the Prognostic Biomarkers for Bladder Carcinoma.Frontiers in oncology · 2022Article
- A Necroptosis-Related lncRNA to Develop a Signature to Predict the Outcome, Immune Landscape, and Chemotherapeutic Responses in Bladder Urothelial Carcinoma.Frontiers in oncology · 2022Article
- Comprehensive Characterization of Necroptosis-Related lncRNAs in Bladder Cancer Identifies a Novel Signature for Prognosis Prediction.Disease markers · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveBladder cancer (BC) is the most common malignancy in the urinary system and is prone to recurrence and metastasis. Pyroptosis is a kind of cell necrosis that is triggered by the gasdermin protein family. lncRNAs are noncoding RNAs that are more than 200 nucleotides long. Both pyroptosis and lncRNAs are associated with tumor development and progression. This study is aimed at exploring and establishing a prognostic signature of BC based on pyroptosis-related lncRNAs.
methodsIn this study, The Cancer Genome Atlas (TCGA) database provided us with the RNA sequencing transcriptome data of bladder cancer patients, and we identified differentially expressed pyroptosis-related lncRNAs in bladder cancer. Then, the prognostic significance of these lncRNAs was assessed using univariate Cox regression analysis and LASSO regression analysis. Subsequently, 4 pyroptosis-related lncRNAs, namely, AL121652.1, AL161729.4, AC007128.1, and AC124312.3, were identified by multivariate Cox regression analysis, thus constructing the prognostic risk model. Then, we compared the levels of immune infiltration, differences in cell function, immune checkpoints, and m6A-related gene expression levels between the high- and low-risk groups.
resultPatients were divided into low-risk or high-risk groups based on the median risk score. Kaplan-Meier survival analysis indicated that the overall survival of bladder cancer patients in the low-risk group was substantially superior to that in the high-risk group (
conclusionTherefore, this prognostic risk model is based on the level of pyroptotic lncRNAs, which is conducive to individualized assessment of the risk of patients and provides a reference for clinical treatment. This will also help provide insights into the prognosis and treatment of bladder cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.